Transcranial magnetic stimulation in obsessive compulsive disorder: a double-blind, cross over, placebo-controlled trial

被引：2
|
作者：
Ziblak, A. [1 ]
Tumkaya, S. [1 ]
Kashyap, H. [2 ]
机构：
[1] Pamukkale Univ, Psychiat, Denizli, Turkey
[2] NIMHANS, Clin Psychol, Bengaluru, India
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.euroneuro.2019.12.099
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.402
引用
收藏
页码：S75 / S76
页数：3
相关论文
共 50 条
  • [31] Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: A randomized, multicenter, double-blind, placebo-controlled trial
    Geller, DA
    Wagner, KD
    Emslie, G
    Murphy, T
    Carpenter, DJ
    Wetherhold, E
    Perera, P
    Machin, A
    Gardiner, C
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2004, 43 (11): : 1387 - 1396
  • [32] Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double-blind, placebo-controlled, cross-over study
    Ruijs, Titia Q.
    Heuberger, Jules A. A. C.
    de Goede, Annika A.
    Ziagkos, Dimitrios
    Otto, Marije E.
    Doll, Robert J.
    van Putten, Michel J. A. M.
    Groeneveld, Geert Jan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (06) : 2926 - 2937
  • [33] A randomized double-blind trial of repetitive transcranial magnetic stimulation in obsessive -compulsive disorder with three months follow-up
    Gomes, Pablo Oliveira
    Rosa, Moacyr A.
    Allam, Nasser
    de Souza, Everton Rodrigues
    Brasil-Neto, Joaquim
    JOURNAL OF ECT, 2012, 28 (02) : 149 - 149
  • [34] Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial
    Dannon, PN
    Sasson, Y
    Hirschmann, S
    Iancu, I
    Grunhaus, LJ
    Zohar, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2000, 10 (03) : 165 - 169
  • [35] Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial
    Tilaki, Erfaneh Hajian
    Hasanzadeh, Alireza
    Shalbafan, Mohammadreza
    Moghaddam, Hossein Sanjari
    Shamabadi, Ahmad
    Boroon, Mahsa
    Akhondzadeh, Shahin
    CLINICAL NEUROPHARMACOLOGY, 2023, 46 (05) : 175 - 180
  • [36] Naproxen adjunct to fluoxetine for moderate-to-severe obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial
    Shamabadi, Ahmad
    Motavalian, Zahra
    Farahmand, Yalda
    Farahmand, Kimia
    Arabzadeh Bahri, Razman
    Askari, Sanaz
    Ansari, Sahar
    Fallahzadeh, Mohammadali
    Shalbafan, Mohammdreza
    Akhondzadeh, Shahin
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2024, 78 (12) : 810 - 817
  • [37] A double-blind placebo-controlled trial of risperidone in autistic disorder
    McDougle, C
    Aman, MG
    McCracken, JT
    Scahill, L
    Tierney, E
    Vitiello, B
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S327 - S328
  • [38] Double-blind, placebo-controlled trial of venlafaxine for panic disorder
    Pollack, MH
    Worthington, JJ
    Otto, MW
    Smoller, JW
    Maki, KM
    Rudolph, R
    Rosenbaum, JF
    PSYCHOPHARMACOLOGY BULLETIN, 1996, 32 (03) : 496 - 496
  • [39] Repetitive transcranial magnetic stimulation as a treatment for Alzheimer's disease: A randomized placebo-controlled double-blind clinical trial
    Moussavi, Zahra
    Uehara, Maria
    Rutherford, Grant
    Lithgow, Brian
    Millikin, Colleen
    Wang, Xikui
    Saha, Chandan
    Mansouri, Behzad
    Omelan, Craig
    Fellows, Lesley
    Fitzgerald, Paul B.
    Koski, Lisa
    NEUROTHERAPEUTICS, 2024, 21 (03)
  • [40] Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study
    Hollander, E
    Rossi, NB
    Sood, E
    Pallanti, S
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2003, 6 (04): : 397 - 401
12345